This trial is for the ARQL drug+anastrozole. How do we know that anastrozole alone doesn't account for the bulk, if not all, of the activity in this patient population?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.